Abstract: With the introduction of tyrosine kinase inhibitor(TKI), the treatment of chronic myeloid leukemia(CML) has made unprecedented breakthroughs, greatly improving the survival and prognosis of patients with CML. Many clinical trials currently have shown that some patients with CML, after receiving TKI treatment and maintaining a deep molecular response, can be successfully discontinued after several years. This article mainly summarizes the clinical trials of TKI in the treatment of CML patients who stop taking drugs after after receiving deep molecular remission, and how to grasp safe withdrawal and achieve treatment-free remission.